SRRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, favorable analyst ratings, and upcoming regulatory milestones that could drive significant growth. Despite no immediate trading signals, the current price trend and sentiment suggest potential upside.
The MACD histogram is positive and expanding (0.169), indicating bullish momentum. RSI is neutral at 64.136, and moving averages are converging, suggesting a potential breakout. The stock is trading near resistance levels (R1: 47.491, R2: 48.676), with strong support at 45.573. Overall, the technical indicators suggest a positive trend.
FDA acceptance of apitegromab application with a September 30 action date, indicating potential approval and launch.
Analysts have raised price targets, with a consensus range of $55-$65, reflecting confidence in the company's growth prospects.
Manufacturing setbacks have been addressed, de-risking the approval process.
Apitegromab has blockbuster potential in treating spinal muscular atrophy, a significant market opportunity.
Slightly bearish options sentiment in the short term.
Lack of recent insider or hedge fund buying activity, indicating neutral institutional sentiment.
No financial data available for the latest quarter.
Analysts are overwhelmingly positive on SRRK, with multiple firms maintaining Buy or Strong Buy ratings and raising price targets. JPMorgan, H.C. Wainwright, Barclays, and others have expressed confidence in the company's regulatory and commercial readiness, with price targets ranging from $55 to $65.
